CJC-1295 vs Ipamorelin
A side-by-side research comparison of CJC-1295 and Ipamorelin across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | CJC-1295 | Ipamorelin |
|---|---|---|
| Full name | CJC-1295 (Modified GRF 1-29) | Ipamorelin (Selective GH Secretagogue) |
| Category | Growth Hormone | Growth Hormone |
| Status | Research compound | Research compound |
| Mechanism | Binds GHRH receptors on anterior pituitary somatotrophs, stimulating cAMP-dependent GH synthesis and pulsatile release. | Selectively activates GHSR on pituitary somatotrophs. Unlike GHRP-6 and hexarelin, does not significantly activate ACTH or prolactin-releasing pathways. |
| Molecular weight | 3,368 Da (without DAC) | 711.9 Da |
| Half-life | 30 minutes (no DAC) / 8 days (with DAC) | 2 hours |
| Bioavailability | High (SubQ) | High (SubQ) |
| Typical dose | 100-300 mcg | 100-300 mcg |
| Frequency | 1-3x daily (no-DAC) | 1-3x daily |
| Route | Subcutaneous injection | Subcutaneous injection |
CJC-1295 reported benefits
- Increased GH production
- Improved body composition
- Enhanced recovery
- Better sleep quality
- Anti-aging effects
- Fat loss
Ipamorelin reported benefits
- Clean GH release
- No cortisol or prolactin increase
- Improved sleep
- Fat loss
- Joint support
- Anti-aging benefits
Related comparisons
Research and educational reference only. Not medical advice.